MARKETS / NASDAQ / NSPR
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

InspireMD, Inc. NSPR

16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$9.0M
▲ 28.1% vs FY2024
EPS · FY25
$-0.76
Dividend / sh · FY25
Payout · FY25
ROE · FY25
-106.9%
Net margin · FY25
-543.3%
Dividend coverage
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 9.0M
Revenue, FY2025 · full 16-year series below
Revenue Net income
0.00250.0050.00750.010.0-0.0200920122016201920222025
0.00250.0050.00750.010.0-0.02016201920222025

The company lost 543 cents on every revenue dollar this year.

Per share
USD -0.76
Diluted EPS, FY2025
EPS
0.40.81.2-0.76200920122016201920222025
0.40.81.2-0.762016201920222025

The company pays no cash dividend.

Profitability
-106.9%
Return on equity, FY2025
ROE
0.250.50.751-106.9%200920122016201920222025
0.250.50.751-106.9%2016201920222025
Operating margin-552.6%
Net margin-543.3%
Return on assets-84.0%

Each USD of equity lost 107 cents this year.

Returned to shareholders
returned in FY2025 · dividends + net buybacks
Dividends paid
Net buybacks
Share of profit
Consecutive raises

Growth
+29.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+20.2%
+29.3%
+14.5%
+4.1%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.04B
Shares outstanding, FY2025
0.050.04200920122016201920222025
0.000.042016201920222025
Change, 5 years
Change, 10 years

A share split breaks the comparison across the period, so we leave it out.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 69.4M
total assets, end of FY2025
Total assetsUSD 69.4M
EquityUSD 55.2M
CashUSD 8.9M
Current ratio5.74×

Equity funds 80% of total assets.

History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2012
2011
2010
2009
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
·
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.76
−0.76
−0.82
−2.35
−2.03
−6.97
−4.80
−16.67
−34.98
−207.72
−55.85
−7.09
−1.39
−1.04
−0.07
−0.06
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−106.9
−84.7
−70.0
−72.6
−65.3
−120.2
−141.9
−126.0
−249.2
−1539.8
·
·
−272.3
−787.0
·
·
Shares out B
0.04
0.03
0.02
0.01
0.01
0.00
0.00
0.04
0.00
0.00
0.00
0.00
0.03
0.02
0.05
·

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
60 of 60
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed